Press enter or spacebar to select a desired language.
Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

2271 - 2280 of 3609 results found

Nationale VersorgungsLeitlinie (NVL) Nierenerkrankungen bei Diabetes im Erwachsenenalter

MeSH Terms
Diabetes Mellitus (C18.452.394.750); Diabetes Complications (C19.246.099)
Guideline Contact
Corinna Schaefer ([email protected])
English Title Translation
Diabetic nephropathy in adults – German National Disease Management Guideline
Publication Scope
assessment
management
Countries of Application
Germany
Guideline Publication Status
Under Review
Languages
German
Authors
AQuMed/AEZQ (DE)
Publication Year
2010

Nationale VersorgungsLeitlinie (NVL) Therapie des Typ-2-Diabetes

MeSH Terms
Glucose Metabolism Disorders (C18.452.394); Diabetes Mellitus; Type 2 (C19.246.300)
Guideline Contact
Corinna Schaefer ([email protected])
English Title Translation
Therapy of type 2 diabetes – German National Disease Management Guideline
Publication Scope
management
Countries of Application
Germany
Guideline Publication Status
Under Review
Languages
German
Authors
AQuMed/AEZQ (DE)
Publication Year
2013

Necesidades en cuidados paliativos de las enfermedades no oncológicas. Un estudio cualitativo desde la perspectiva de profesionales, pacientes y personas cuidadoras (Informe nº: Osteba E12/02)

MeSH Terms
Palliative Care (E02.760.666); Chronic Disease (C23.550.291.500); Needs Assessment (N05.300.537); Qualitative Research (H01.770.644.241.850)
English Title Translation
Palliative care requirements in the case of non-oncological diseases. A qualitative study from the perspective of professionals, patients and carers
Publication Scope
assessment
management
Countries of Application
Spain
Guideline Publication Status
Published
Languages
Spanish
Authors
OSTEBA (ES)
Publication Year
2012

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

MeSH Terms

ovarian neoplasms, ovary tumour, ovary, fallopian tube, primary peritoneal, cancer, neoplasm, adenocarcinoma, carcinoma, malignant, tumour, metastases, drug therapy, antineoplastic agent, chemotherapy, adjuvant chemotherapy, consolidation chemotherapy, antineoplastic combined chemotherapy protocols, molecular targeted therapy, systemic, biologic, targeted, immunotherapy, hormone, maintenance, therapy, treatment, adriamycin, carboplatin, cisplatin, platinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum, cisdiamminedichloroplatinum, cyclophosphamide, doxorubicin, epirubicin, gemcitabine, irinotecan, isosfamide, paclitaxel, taxane, etoposide, platinum, MEK inhibitor, PD-325901, selumetinib, AZD6244, PD184352, CI-1040, PD035901, TAK-733, binimetinib, MEK162, ARRY-162, ARRY-438162, trametinib, GSK1120212, mekinist, cobimetinib, cotellic, XL518, GDC-0973, poly(ADP-ribose) polymerase inhibitors, olaparib, AZD2281, lynparza, AZD221, veliparib, ABT888, talazoparib, BMN673, nintedanib, iniparib, oregovomab, abagovomab, CA-125, MUC 16, pazopanib, niraparib, MK4827, rucaparib, PF-01367338, AG014699, rapamune, rapamycin, sirolimus, I2190A, AY 22989, cediranib, recentin, AZD2171, antibodies, monoclonal, humanized, bevacizumab, avastin, mTOR inhibitor, temsirolimus, CCI 779, torisel, everolimus, afinitor, certican, RAD001, SDZ-RAD, deforolimus, ridaforolimus, MK8669, AP23573, BRAF inhibitor, PLX8394, vemurafenib, RG7204, R05185426, PLX4032 or PLX-4032, zelboraf, dabrafenib, tafinlar, GSK2118436, tumour-infiltrating lymphocyte therapy, cytokines, IL-2, interferon, IFN-alpha, immune checkpoint inhibitor, thalidomide, sedoval, thalomid, revlimid, lenalidomide, CC5013, S-3APG, pomalidomide, pomalyst, imnovid, CC-4047, bacille calmette-guerin, tamoxifen, tomaxithen, zitazonium, soltamox, novaldex, nolvadex, ICI47699, ICI46474, fareston, fulvestrant, faslodex, ZM 182780, ICI182780, letrozole, femara, CGS-20267, anastrozole, arimidex, ICI D1033, ZD-1033, examestane, aromasin, FCE-24304, cystorelin, dirigestran, factrel, GnRH, gonadoliberin, luliberin, gonadotropin-releasing hormone, kryptocur, LFRH, luteinizing hormone-releasing hormone, angiogenesis inhibitor, aromatase inhibitor, topotecan, hycamtamine, NSC-609699, SKF104864A, oxaliplatin, eloxatin, docetaxol, taxotere, RP-56976, trabectedin, ecteinascidin, yondelis, ET-743, NSC 684766

Guideline Contact
Raymond Poon; [email protected]
Keywords
ovarian neoplasms, ovary tumour, fallopian tube, primary peritoneal, drug therapy, antineoplastic combined chemotherapy protocols
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Publication Date
2021-01-27
Date of Last Evidence Search
Oct-20
Methods Applied
Systematic review-based, Externally reviewed, Evidence quality assessment, GRADE approach
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2021

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

MeSH Terms
Neoplasms (C04); Chemotherapy; Adjuvant (E02.186.170); Chemotherapy; Adjuvant (E02.319.170); Ovarian Neoplasms (C04.588.322.455)
Guideline Contact
[email protected]
Publication Date
08-Aug-16
Publication Scope
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
Publication Year
2016
My Saved Lists